Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POSIMIR vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Single-dose administration in adults for local analgesia at the surgical site following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty (TKA).
Local anesthesia for dental procedures requiring infiltration or nerve block anesthesia
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.
For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
Primarily hepatic via conjugation with glucuronic acid; major metabolite is 4-hydroxybupivacaine. CYP3A4 and CYP1A2 are involved in minor oxidative metabolism.
Articaine is metabolized primarily by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid; levonordefrin is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
Approximately 97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Articaine: approximately 70-80% bound, primarily to albumin. Levonordefrin: not reported.
Volume of distribution is approximately 1.9 L/kg, indicating extensive distribution into tissues.
Articaine: Vd ~1.0 L/kg. Clinical meaning: moderate distribution into total body water, consistent with local anesthetic profile.
Not applicable via oral route; only administered as a local infiltration. Systemic bioavailability after local administration is approximately 100% locally, but systemic levels are low due to slow release from the formulation.
Not applicable for local anesthetic; administered parenterally (infiltration/block). By submucosal injection:100% systemically available (though redistributes locally).
No dose adjustment is required for mild to moderate renal impairment. Safety and efficacy have not been established in severe renal impairment (GFR <30 m L/min), use with caution.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
No dose adjustment is required for mild (Child-Pugh A) hepatic impairment. For moderate (Child-Pugh B) impairment, consider cautious use with monitoring for toxicity. Contraindicated in severe (Child-Pugh C) hepatic impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Consider 50% dose reduction. Child-Pugh C: Avoid use or reduce dose by 75%; monitor for systemic toxicity.
Safety and efficacy in pediatric patients have not been established. No standard dosing guidelines exist.
Weight-based: 0.5-1.0 mg/kg per injection site, not to exceed 3.5 mg/kg total; maximum single dose 200 mg. Adjust for age and body weight; use lower concentrations (1:100,000 epinephrine equivalent).
No specific dose adjustment is recommended, but elderly patients may have increased sensitivity and reduced clearance. Use with caution, monitoring for cardiac and neurological toxicity.
Reduce dose by 20-50% due to increased risk of cardiovascular and central nervous system effects; consider lower concentration and slower administration.
Not approved for use in: obstetrical paravertebral block, epidural or intrathecal administration. Risk of cardiac arrest and death has been reported with bupivacaine use via these routes.
None
Risk of overdose and toxicity with unintentional intravascular injection or excessive dosing.,Do not use in patients with hypersensitivity to bupivacaine or any amide-type local anesthetic.,Not recommended for patients with severe hepatic impairment.,Safety in pediatric patients not established.,Use with caution in patients with cardiovascular disease, especially those with impaired cardiac conduction.,May cause methemoglobinemia in susceptible patients.,Chondrolysis with intra-articular use (not indicated for such use).
Risk of methemoglobinemia, especially with higher doses, in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or exposure to oxidizing agents,Cardiovascular effects due to levonordefrin, including hypertension, hypotension, tachycardia, and cardiac arrhythmias; use caution in patients with cardiovascular disease, hypertension, or hyperthyroidism,Allergic reactions including anaphylaxis have been reported,Systemic toxicity due to inadvertent intravascular injection; observe proper injection technique,Use caution in patients with impaired liver function or severe renal impairment
Hypersensitivity to bupivacaine or any component of the formulation,Obstetrical paravertebral block,Epidural or intrathecal administration
Hypersensitivity to articaine, levonordefrin, or any component of the formulation,Hypersensitivity to amide-type local anesthetics or sympathomimetic amines,Severe or uncontrolled hypertension,Concurrent use of MAO inhibitors or within 14 days of discontinuation (due to risk of hypertensive crisis)
No known food interactions. Avoid alcohol for 24 hours post-administration to minimize additive CNS depression.
No significant food interactions. Avoid alcohol consumption for at least 24 hours after the procedure as it may increase the risk of bleeding at the injection site.
POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenicity is unknown; bupivacaine crosses the placenta. Second and third trimesters: Potential for fetal bradycardia, CNS depression, and neurobehavioral effects. Use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause uteroplacental vasoconstriction and fetal hypoxia; avoid use during labor due to risk of maternal hypertension and fetal bradycardia.
Bupivacaine is excreted in breast milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.3. The relative infant dose is estimated to be <2% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding, but caution is advised in infants with impaired hepatic function.
Minimal excretion into breast milk; M/P ratio unknown. Levonordefrin has low oral bioavailability. Considered compatible with breastfeeding; monitor infant for irritability or tachycardia. Avoid application to nipples.
No specific dose adjustments are recommended for POSIMIR in pregnancy. However, physiological changes (increased plasma volume, altered hepatic metabolism) may affect bupivacaine pharmacokinetics, potentially increasing systemic absorption. Use lowest effective dose and monitor for signs of toxicity.
No standard dose adjustment required. Use lowest effective dose and shortest duration. Increased plasma volume in pregnancy may slightly reduce peak concentrations, but no dose adjustment is routinely recommended. Avoid use in preeclampsia or severe hypertension.
POSIMIR (bupivacaine) is a long-acting, non-opioid local analgesic administered via infiltration into the surgical site. Its liposomal bupivacaine formulation provides up to 72 hours of analgesia. Do not use for intra-articular, epidural, or intrathecal administration; risk of chondrolysis and nerve injury. Avoid concomitant use with other local anesthetics. Monitor for signs of systemic toxicity (e.g., CNS excitation, cardiac depression). Not recommended in patients with hepatic impairment or myasthenia gravis.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a dental anesthetic containing articaine HCl 4% with epinephrine 1:100,000. Levonordefrin is a vasoconstrictor added to prolong local anesthesia. Avoid use in patients with sulfite sensitivity (articaine contains sodium metabisulfite). Maximum dose: 7 mg/kg (articaine) and not to exceed 0.5 mg levonordefrin per appointment. Do not inject into inflamed or infected tissues due to increased absorption. Aspirate before injection to prevent intravascular administration.
POSIMIR is a long-acting anesthetic injected at the surgical site to reduce pain for up to 3 days.,Do not drive or operate machinery for at least 48 hours after administration due to potential dizziness or sedation.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Avoid applying heat or ice directly to the injection site unless advised by your surgeon.,You may still feel some sensation; use prescribed rescue analgesics as needed.,Do not use additional numbing creams or sprays near the surgical site.,Contact your doctor if you experience severe headache, blurred vision, or ringing in ears.,If you are pregnant or breastfeeding, discuss risks with your healthcare provider.
You may experience numbness in your mouth, lips, and tongue for several hours after the injection; avoid eating or drinking hot liquids until sensation returns to prevent burns.,Do not chew on the numb area to avoid accidental injury.,If you have a history of sulfite allergy, inform your dentist before the procedure.,Contact your dentist immediately if you experience severe headache, rapid heartbeat, or difficulty breathing after the injection.,This medication can cause temporary dizziness or lightheadedness; avoid driving until the effects have worn off.
No interactions on record
"Levonordefrin, a vasoconstrictor with beta-agonist activity, may counteract the beta-blocking effects of pindolol, leading to unopposed alpha-adrenergic stimulation and potential hypertensive crisis. Additionally, pindolol's intrinsic sympathomimetic activity (ISA) may interact with levonordefrin, increasing the risk of cardiac arrhythmias and AV block due to conflicting adrenergic signaling. Clinically, this can result in severe hypertension, bradycardia, or heart block, especially in patients with underlying cardiovascular disease."
"Mianserin, a tetracyclic antidepressant with potent alpha-2-adrenergic receptor antagonism, can reduce the vasopressor response to Levonordefrin, a direct-acting alpha-1 adrenergic agonist. This interaction occurs because Mianserin blocks presynaptic alpha-2 receptors, leading to increased norepinephrine release and potential receptor desensitization, as well as possible competitive antagonism at the alpha-1 receptor. Clinically, this may result in diminished efficacy of Levonordefrin when used as a local vasoconstrictor during dental or surgical procedures, potentially leading to inadequate hemostasis or reduced local anesthesia duration."
"Levonordefrin, a sympathomimetic amine with alpha- and beta-adrenergic agonist activity, can enhance the negative dromotropic effect of arotinolol, a non-selective beta-blocker with intrinsic sympathomimetic activity. This results in additive depression of atrioventricular (AV) nodal conduction, potentially leading to prolonged PR interval, second- or third-degree AV block, and symptomatic bradycardia. Clinically, patients may present with dizziness, syncope, or hemodynamic instability, particularly in those with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POSIMIR vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
POSIMIR is a Local Anesthetic that works by Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POSIMIR and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POSIMIR is: Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POSIMIR and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POSIMIR is classified as Category C. POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenici. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.